BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says.
Get this delivered to your inbox, and more info about our products and services.
The investment firm initiated coverage of the biopharma stock at a outperform rating.
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
HSBC signals a potential cooling period for the red-hot obesity drug trade.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
